Assistant Professor & Principal Investigator,
Pharmaceutics and Pharmaceutical Chemistry
Coss.16@osu.edu
Chris Coss, PhD.
Principal Investigators
Mitch A. Phelps, PhD.
Professor & Principal Investigator
Pharmaceutics and Pharmaceutical Chemistry
Phelps.32@osu.edu
Professional Interests
Mitch Phelps’ group is involved in both pre-clinical and clinical development of numerous small molecule anti-cancer and immuno-modulatory agents under development here at OSU. Their work aims to understand the mechanisms involved in the absorption, distribution, metabolism, and excretion (i.e. pharmacokinetics, PK) of these agents, and how both the PK and pharmacodynamic (PD) effects of these agents are altered by genetic differences (polymorphisms) among individuals (i.e. pharmacogenetics, PG).
Education
2005, PhD, The Ohio State University, Biophysics
1999, MLHR, The Ohio State University, Labor and Human Resources
1992, BA, Ohio Wesleyan University, Physics
Honors
Outstanding Graduate Student Award, 2005
Predoctoral Fellowship, 2004
Predoctoral Fellowship, 2003 – 2004
Ray Travel Award, 2003
Hazel Brown Teaching Award, 2001
- Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
No approved therapy exists for cancer-associated cachexia. The colon-26 mouse model of cancer cachexia mimics recent late-stage… Read more: Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor - Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression
Owing to the marked sexual dimorphism of hepatocellular carcinoma (HCC), sex hormone receptor signaling has been implicated… Read more: Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression - Population pharmacokinetics of lenalidomide in patients with B-cell malignancies
Aims: Lenalidomide is an immunomodulatory imide drug used broadly in the treatment of multiple myeloma and lymphoma. It… Read more: Population pharmacokinetics of lenalidomide in patients with B-cell malignancies